Physician profile
Daniel Eric Campbell Clark
NPI 1215788682
$4,446.33
in general payments reported to CMS, 2019-2025
20 companies · $2,931 in 2025
The $2,931 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,515 · 2025: $2,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,446.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $726.71 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $587.42 | 2024-2025 | Ingrezza |
| Abbvie INC. | $478.60 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $408.67 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $367.27 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $323.23 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $315.94 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Corium, LLC | $311.24 | 2024-2025 | Azstarys |
| Alkermes, INC. | $174.98 | 2024-2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $139.96 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $109.92 | 2024 | |
| Lundbeck LLC | $105.28 | 2024-2025 | Rexulti |
| Tris Pharma INC | $83.02 | 2024-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $73.52 | 2024-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $73.41 | 2024-2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $68.22 | 2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $33.86 | 2025 | Austedo Xr |
| Noven Therapeutics, LLC | $29.26 | 2025 | Xelstrym, Secuado |
| Indivior INC. | $20.45 | 2024 | Perseris |
| Axsome Therapeutics, INC. | $15.37 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.